
    
      This is a randomized, double-blinded, controlled, Phase I study in healthy male and
      non-pregnant female subjects, 18 to 49 years old, inclusive, designed to assess the safety,
      reactogenicity, and immunogenicity of an intramuscular subvirion inactivated monovalent
      influenza A/H5N1 (HA of A/Indonesia/05/2005) virus vaccine manufactured by Sanofi Pasteur
      administered at different dosage levels (3.75, 7.5 or 15 mcg) given with the MF59 adjuvant
      manufactured by Novartis or PBS diluent.
    
  